p16抑癌基因产物在原发性肝细胞癌中的表达及临床意义

Expression and clinical significance of anti-oncogene p16in Hepatocarcinoma(HCC)

目的 分析p16蛋白测定在肝癌临床中的地位 ,并推测p16基因在肝细胞癌发生发展过程中的作用。方法 采用免疫组化SP法测定34例原发性肝细胞癌、20例癌旁肝细胞中p16蛋白表达 ,分析与肝细胞癌组织学分级、TNM分期、生存预后等关系。结果 64.7%的原发性肝细胞癌p16蛋白表达阳性 ,35.3 %阴性 ,癌旁肝组织表达100%阳性。两者差异显著 (P<0.05)。组织学分化Ⅳ级的肝细胞癌表达阳性率为41.7 %、Ⅰ～Ⅲ级分化的阳性率75%～77.8% ,对比有差异显著性 (P<0.05)。TNMⅠ～Ⅳ期各组间p16蛋白的表达无差异。术后1、3年生存率在p16蛋白阳性者分别为93.7%和72.7% ,阴性者分别为77.8%和60 %。结论 部分肝细胞癌组织存在p16蛋白的表达缺失现象。p16蛋白表达障碍可能与肝细胞癌的发生和组织分化有关。p16蛋白是否可作为本病恶性行为判断、预后分析的参考指标值得进一步研究。

Objective To explore effect of p16gene in the development of HCC. Methods The expression of p16gene in34cases of HCC and20cases of para-carcinoma was detected by immunohistochemistry SP,and the relationships between its expression and histology grade,TNMstaging of carcinoma and prognosis of the patients were analyzed respectively. Results Positive expressions in HCC64.7%and100%in para-carcinoma,and41.7%in gradeⅣHCC and75%～77.8%in gradeⅠ～III respectively.There is significant difference between the2groups(p<0.05).There is no difference in expression of p16among TNMstagingⅠ～Ⅳ.The1,3years survival were93.7%and72.7%in positive expression group,and77.8%and60%in negative group respectively. Conclusions Expression absence of p16gene exist in part of HCC cell,which may be related with development and histo-differentiation of HCC.